Riegel Adam C, Nosrati Jason D, Sidiqi Baho U, Cooney Ann, Wuu Yen-Ruh, Lee Lucille, Potters Louis
Department of Radiation Medicine, Northwell Health, Lake Success, New York.
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York.
Adv Radiat Oncol. 2022 Dec 29;8(3):101156. doi: 10.1016/j.adro.2022.101156. eCollection 2023 May-Jun.
Intermediate- and high-risk prostate cancer patients undergoing combination external beam radiation therapy (EBRT) and low dose rate (LDR) brachytherapy have demonstrated increased genitourinary (GU) toxicity. We have previously demonstrated a method to combine EBRT and LDR dosimetry. In this work, we use this technique for a sample of patients with intermediate- and high-risk prostate cancer, correlate with clinical toxicity, and suggest preliminary summed organ-at-risk constraints for future investigation.
Intensity modulated EBRT and Pd-based LDR treatment plans were combined for 138 patients using biological effective dose (BED) and deformable image registration. GU and gastrointestinal (GI) toxicity were compared with combined dosimetry for the urethra, bladder, and rectum. Differences between doses in each toxicity grade were assessed by analysis of variance (α = 0.05). Combined dosimetric constraints are proposed using the mean organ-at-risk dose, subtracting 1 standard deviation for a conservative recommendation.
The majority of our 138-patient cohort experienced grade 0 to 2 GU or GI toxicity. Six grade 3 toxicities were noted. Mean prostate BED D90 (± 1 standard deviation) was 165.5±11.1 Gy. Mean urethra BED D10 was 230.3±33.9 Gy. Mean bladder BED was 35.2±11.0 Gy. Mean rectum BED D2cc was 85.6±24.3 Gy. Significant dosimetric differences between toxicity grades were found for mean bladder BED, bladder D15, and rectum D50, but differences between individual means were not statistically significant. Given the low incidence of grade 3 GU and GI toxicity, we propose urethra D10 <200 Gy, rectum D2cc <60 Gy, and bladder D15 <45 Gy as preliminary dose constraints for combined modality therapy.
We successfully applied our dose integration technique to a sample of patients with intermediate- and high-risk prostate cancer. Incidence of grade 3 toxicity was low, suggesting that combined doses observed in this study were safe. We suggest preliminary dose constraints as a conservative starting point to investigate and escalate prospectively in a future study.
接受外照射放疗(EBRT)与低剂量率(LDR)近距离放疗联合治疗的中高危前列腺癌患者已出现泌尿生殖系统(GU)毒性增加的情况。我们之前展示了一种将EBRT和LDR剂量测定相结合的方法。在这项研究中,我们将该技术应用于一组中高危前列腺癌患者,将其与临床毒性相关联,并提出初步的危及器官总剂量限制以供未来研究。
使用生物等效剂量(BED)和可变形图像配准技术,为138例患者制定了调强EBRT和基于钯的LDR治疗计划。将GU和胃肠道(GI)毒性与尿道、膀胱和直肠的联合剂量测定结果进行比较。通过方差分析(α = 0.05)评估各毒性等级剂量之间的差异。使用危及器官平均剂量减去1个标准差来提出联合剂量测定限制,以给出保守建议。
在我们的138例患者队列中,大多数患者经历了0至2级的GU或GI毒性。记录到6例3级毒性反应。前列腺平均BED D90(±1个标准差)为165.5±11.1 Gy。尿道平均BED D10为230.3±33.9 Gy。膀胱平均BED为35.2±11.0 Gy。直肠平均BED D2cc为85.6±24.3 Gy。在膀胱平均BED、膀胱D15和直肠D50方面,毒性等级之间存在显著的剂量测定差异,但个体平均值之间的差异无统计学意义。鉴于3级GU和GI毒性的发生率较低,我们提出尿道D10 <200 Gy、直肠D2cc <60 Gy和膀胱D15 <45 Gy作为联合治疗模式的初步剂量限制。
我们成功地将剂量整合技术应用于一组中高危前列腺癌患者。3级毒性的发生率较低,表明本研究中观察到的联合剂量是安全的。我们建议将初步剂量限制作为一个保守的起点,以便在未来的研究中进行前瞻性研究和剂量递增。